BACKGROUND: Venous thromboembolism (VTE) is a serious complication of cancer and its treatment. The current study assessed the risk and clinical predictors of VTE in breast cancer patients by time since diagnosis. METHODS: This Swedish population-based study included 8338 breast cancer patients diagnosed from 2001 to 2008 in the Stockholm-Gotland region with complete follow-up until 2012. Their incidence of VTE was compared with the incidence among 39,013 age-matched reference individuals from the general population. Cox and flexible parametric models were used to examine associations with patient, tumor, and treatment characteristics, accounting for time-dependent effects. RESULTS: Over a median follow-up of 7.2 years, 426 breast cancer patients experienced a VTE event (cumulative incidence, 5.1%). The VTE incidence was 3-fold increased (hazard ratio [HR], 3.28; 95% confidence interval [CI], 2.87-3.74) in comparison with the incidence in the general population and was highest 6 months after diagnosis (HR, 8.62; 95% CI, 6.56-11.33) with a sustained increase in risk thereafter (HR at 5 years, 2.19; 95% CI, 1.80-2.67). Independent predictors of VTE included the following: older age, being overweight, preexisting VTE, comorbid disease, tumor size > 40 mm, progesterone receptor (PR)-negative status, more than 4 affected lymph nodes, and receipt of chemo- and endocrine therapy. The impact of chemotherapy was limited to early-onset VTE, whereas comorbid disease and PR-negative status were more strongly associated with late-onset events. CONCLUSIONS: This study confirms the long-term risk of VTE in breast cancer patients and identifies a comprehensive set of clinical risk predictors. Temporal associations with patient, tumor, and treatment characteristics provide insight into the time-dependent etiology of VTE. Cancer 2017;123:468-475.
BACKGROUND:Venous thromboembolism (VTE) is a serious complication of cancer and its treatment. The current study assessed the risk and clinical predictors of VTE in breast cancerpatients by time since diagnosis. METHODS: This Swedish population-based study included 8338 breast cancerpatients diagnosed from 2001 to 2008 in the Stockholm-Gotland region with complete follow-up until 2012. Their incidence of VTE was compared with the incidence among 39,013 age-matched reference individuals from the general population. Cox and flexible parametric models were used to examine associations with patient, tumor, and treatment characteristics, accounting for time-dependent effects. RESULTS: Over a median follow-up of 7.2 years, 426 breast cancerpatients experienced a VTE event (cumulative incidence, 5.1%). The VTE incidence was 3-fold increased (hazard ratio [HR], 3.28; 95% confidence interval [CI], 2.87-3.74) in comparison with the incidence in the general population and was highest 6 months after diagnosis (HR, 8.62; 95% CI, 6.56-11.33) with a sustained increase in risk thereafter (HR at 5 years, 2.19; 95% CI, 1.80-2.67). Independent predictors of VTE included the following: older age, being overweight, preexisting VTE, comorbid disease, tumor size > 40 mm, progesterone receptor (PR)-negative status, more than 4 affected lymph nodes, and receipt of chemo- and endocrine therapy. The impact of chemotherapy was limited to early-onset VTE, whereas comorbid disease and PR-negative status were more strongly associated with late-onset events. CONCLUSIONS: This study confirms the long-term risk of VTE in breast cancerpatients and identifies a comprehensive set of clinical risk predictors. Temporal associations with patient, tumor, and treatment characteristics provide insight into the time-dependent etiology of VTE. Cancer 2017;123:468-475.
Authors: Heather Greenlee; Carlos Iribarren; Jamal S Rana; Richard Cheng; Mai Nguyen-Huynh; Eileen Rillamas-Sun; Zaixing Shi; Cecile A Laurent; Valerie S Lee; Janise M Roh; Margarita Santiago-Torres; Hanjie Shen; Dawn L Hershman; Lawrence H Kushi; Romain Neugebauer; Marilyn L Kwan Journal: J Clin Oncol Date: 2022-04-06 Impact factor: 50.717
Authors: F Cavagna; A Pontes; M Cavagna; A Dzik; N F Donadio; R Portela; M T Nagai; L H Gebrim Journal: Curr Oncol Date: 2018-12-01 Impact factor: 3.677
Authors: Haomin Yang; Yudi Pawitan; Wei He; Louise Eriksson; Natalie Holowko; Per Hall; Kamila Czene Journal: Breast Cancer Res Date: 2019-08-16 Impact factor: 6.466
Authors: Helen Strongman; Sarah Gadd; Anthony Matthews; Kathryn E Mansfield; Susannah Stanway; Alexander R Lyon; Isabel Dos-Santos-Silva; Liam Smeeth; Krishnan Bhaskaran Journal: Lancet Date: 2019-08-20 Impact factor: 202.731
Authors: Felipe Cavagna; Anagloria Pontes; Mario Cavagna; Artur Dzik; Nilka F Donadio; Rafael Portela; Michelle T Nagai; Luiz H Gebrim Journal: Contemp Oncol (Pozn) Date: 2017-12-30
Authors: Philippe Debourdeau; Marc Espié; Sylvie Chevret; Joseph Gligorov; Antoine Elias; Pierre François Dupré; Kristell Desseaux; Issa Kalidi; Stephane Villiers; Sylvie Giachetti; Corinne Frere; Dominique Farge Journal: Cancer Med Date: 2017-10-04 Impact factor: 4.452